Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
Fev 2026 – Affilogic is presenting a Poster at World ADC London 2026 : meet us during the poster session to see the poster and learn on the latest data generated on our ODC program in which we use Nanofitins® for targeted delivery of cytotoxic payloads to solid tumors.
Dec 2025 – Affilogic’s CEO presenting at CNS Drug Delivery Summit : Olivier Kitten is presenting at CNS Drug Delivery Summit in Boston latest in-vivo data on our Bus2Brain program, using Nanofitins® for the delivery of biologics into the brain.
Around the world
Affilogic to present at Nucleic Acid Therapeutics and Targeted Delivery 2026
Affilogic is presenting at next Nucleic Acid Therapeutics and Targeted Delivery 2026 in Fairmont Banff Spring – Canada
Mar 09-12, 2026
World ADC LONDON 2026
Affilogic is presenting a poster at next World ADC LONDON 2026 in London – UK
Feb 23-26, 2026
BiotechShowcase / JPM 2026
Affilogic attending next BiotechShowcase/JPM week in San-Francisco- USA
Jan 12-16, 2026
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More